Alkem Laboratories · ALKEM

Alkem trims its India and US growth guidance as its Daman plant waits for the FDA

Quarterly sales rose 13.8%, but management lowered its India and US growth outlook, gave Enzene's break-even a longer date and kept a margin guide that a weaker second half already tests.

3 min read Published on

Published by

Inve Content team

Alkem Laboratories stock page → More news from 13 Nov 2026

Alkem Laboratories reported on 12 November that sales in the September 2026 quarter rose 13.8% from a year earlier, with EBITDA, its profit before depreciation, interest, tax and other income, up a little less. On the same day management lowered what it expects this year from its two biggest drug markets. Sandeep Singh, the managing director, put growth in India, the company's largest business, a point below where he had put it in August: "I think we will end up by around close to 11% of India growth overall."

Alkem cut its India growth guide by a point in the twelve weeks since August

%

India sales growth guide for FY27

  1. 12% Given 20 Aug
  2. 11% Given 12 Nov
Both figures were given as "close to" the number.

The American outlook came down as well. Mr Singh now expects mid-single-digit growth for the year, measured in constant currency, that is, before any gain from exchange rates. In August he had spoken of growth of high single digits to mid, adding that currency would help.

The reason is a factory. Alkem's plant at Daman, on India's west coast, supplied almost half of its US revenue by the company's account in August, and its standing with the US Food and Drug Administration bars new approvals from the site. Three products the company had lined up for launch are waiting. In August management hoped to settle the matter within a year at most. Every response has now been sent, said Amrut Naik, who took over as chief executive of the pharmaceutical business the day before the results: "We are, in fact, waiting for their counter responses in terms of how and when they will come for a reaudit."

The newer businesses have slipped too. In August Alkem said Enzene, its biologics and contract-manufacturing arm, would break even at its US contract plant within four to five quarters. Now an executive put break-even for Enzene as a whole at a year and a half to two years at most, though August's date covered only the US plant. The US application for denosumab, a copy of a bone drug that the company aimed in February to launch by the end of this year, now has to be filed again. Asked about Enzene's hits and misses, Mr Singh listed three and said: "But if I have to pick one, I think it's the BLA disappointment."

Against these trims, the margin looks like spare room. In May the company guided to an EBITDA margin of 20% to 21% for the year, and the first half finished above that range. Management declined to raise it, calling a revision premature, and Mr Singh said the full year might at best match last year's margin, with pressure in the third and fourth quarters. The first half, though, was below the same half a year earlier, and in each of the past two years Alkem's second half has been its weaker one: last year it ran well under the full-year figure. By our arithmetic, if second-half sales match the first half's, matching last year's full-year margin would take a second-half margin of about 19.2%, against 18.3% a year earlier, which is what management's forecast implies.

This year's first-half margin beats the guide but trails last year's; the past two second halves were weaker

%

EBITDA margin

  1. 22.5% H1 FY26
  2. 18.3% H2 FY26
  3. 20.4% FY26
  4. 21.6% H1 FY27
EBITDA as a share of sales, calculated from the filed quarterly results; the FY27 guide is 20% to 21%.

Below EBITDA, the quarter went the other way. Pre-tax profit grew but net profit fell, because the tax rate jumped from a year earlier, when Alkem was still paying the minimum alternate tax, which management said a year ago it would leave once the financial year to March ended. The first-half rate sat above the band the company gave in August. Asked whether the higher depreciation and interest, partly from buying Occlutech, the heart-device maker, were the new norm, an executive said they were.

Tax turned a rise in pre-tax profit into a fall in net profit last quarter

₹ cr

Profit before tax

  1. ₹896 crore Q2 FY26
  2. ₹1,000 crore Q2 FY27

Net profit

  1. ₹779 crore Q2 FY26
  2. ₹667 crore Q2 FY27
Filed consolidated amounts for last quarter and the same quarter a year earlier; the tax rate was 33% against 13%, and 33.0% for the first half against a 30% to 32% guide.

Mr Naik, whose commercial career was spent largely in overseas markets, said he expects to have a clearer view of the path he wants to take in three to four months.

Alkem Laboratories stock page →

The record: full financial tables

Financials

Income statement, last 8 quarters

₹ crore; YoY and margin in %
Quarter endSalesYoYOperating profitOp. marginOther incomePBTNet profit
Sept 20264,552+13.8%1,02522.5%1691,000667
Jun 20263,740+10.9%76620.5%153772521
Mar 20263,603+14.6%51714.3%65423251
Dec 20253,737+10.8%82822.2%90781653
Sept 20254,001+17.2%92123.0%104896779
Jun 20253,371+11.2%73921.9%149771668
Mar 20253,144+7.1%39112.4%146396322
Dec 20243,374+1.5%75922.5%93731641

Balance sheet

₹ crore
As ofEquityDebtInvestmentsFixed assetsCWIPTotal assets
Sept 202614,8652,3102,0735,87816123,060
Mar 202613,8202,0471,8693,87128220,858
Sept 202513,3462,3562,5333,31965320,287
Mar 202511,9851,3811,8462,85254817,691

Cash flow

₹ crore
Year endOperatingInvestingFinancingFree cash flow
Mar 20261,963−1,682−5031,476
Mar 20251,913−1,288−8111,278
Mar 20241,948−1,011−1,1451,761
Mar 20231,682120−1,7611,453